Physician profile
Robert A Dunn
NPI 1972881027
$719.92
in general payments reported to CMS, 2019-2025
11 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.17 · 2020: $70.17 · 2021: $89.70 · 2023: $31.77 · 2024: $176 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $210.04 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $119.72 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $95.14 | 2021-2025 | Breztri |
| Abbvie INC. | $69.51 | 2021-2024 | |
| Lundbeck LLC | $61.36 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $50.18 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $38.72 | 2024-2025 | |
| Lilly USA, LLC | $28.07 | 2024-2025 | Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $16.00 | 2019 | |
| Amgen INC. | $15.75 | 2020 | |
| Grifols USA, LLC | $15.43 | 2024 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.